ADVB

MKT CAP:$6M

Advanced Biomed Inc. Common Stock

Market Cap

$6M

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$5.03-$1.01 (-16.72%)

Apr 21, 2026

Company Details

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+...

CEO

Yi Lu

IPO Date

Mar 6, 2025

Website

www.advanbiomed.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$2M

EPS (Diluted)

-$0.10

Free Cash Flow

-$960.6K

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

Nov 19, 2025

$0EPS -$0.02

Q4 2025

Oct 8, 2025

$0EPS -$0.02

Q2 2025

Apr 15, 2025

$0EPS -$0.04

Q1 2025

Sep 30, 2024

$0EPS -$0.01

FY 2024

Jun 30, 2024

$0EPS -$0.13

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 22	$0	$0	-$1M
Q1 23	$0	$0	-$408.6K
Q2 23	$0	$0	-$853.2K
Q3 23	$0	$0	-$790.2K
Q4 23	$0	$0	-$1M
Q1 24	$0	$0	-$440.2K
Q2 24	$0	$0	-$651.3K
Q4 24	$0	$0	-$704.6K
Q1 25	$0	$0	-$520.0K
Q2 25	$0	$0	-$280.1K
Q4 25	$0	-$2.1K	-$39.3K
Q1 26	$0	$0	-$523.9K

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$2M	-$2M
Q1 23	-$2M	-$2M
Q2 23	-$327.1K	-$477.3K
Q3 23	-$706.4K	-$556.1K
Q4 23	$174.1K	-$36.8K
Q1 24	-$619.1K	-$619.1K
Q2 24	$34.3K	-$13.3K
Q4 24	-$475.8K	-$529.1K
Q1 25	-$29.7K	-$49.7K
Q2 25	-$841.8K	-$831.1K
Q4 25	-$58.6K	-$59.3K
Q1 26	-$20.4K	-$20.4K

Capital Expenditures

Quarter	CapEx
Q4 22	$709.9K
Q1 23	$0
Q2 23	$150.2K
Q3 23	$150.2K
Q4 23	$210.9K
Q1 24	$0
Q2 24	$47.6K
Q4 24	$53.3K
Q1 25	$20.0K
Q2 25	$10.7K
Q4 25	$671
Q1 26	$59

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 23	—	-5.9%
Q1 24	—	+7.7%
Q2 24	—	-23.7%
Q4 24	—	-10.8%
Q1 25	—	-49.0%
Q2 25	—	-36.4%
Q4 25	—	-94.0%
Q1 26	—	-25.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$0	—
Q1 23	$0	—
Q2 23	$0	—
Q3 23	$0	—
Q4 23	$0	—
Q1 24	$0	—
Q2 24	$0	—
Q4 24	$0	—
Q1 25	$0	—
Q2 25	$0	—
Q4 25	$0	—
Q1 26	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 22	$574.3K	$378.5K	—
Q1 23	$116.6K	$240.8K	—
Q2 23	$570.2K	$258.6K	—
Q3 23	$208.2K	$553.4K	—
Q4 23	$488.2K	$498.5K	—
Q1 24	$169.2K	$244.1K	—
Q2 24	$188.4K	$435.9K	—
Q4 24	$209.1K	$177.0K	—
Q1 25	$181.7K	$311.0K	—
Q2 25	$212.4K	$67.7K	—
Q4 25	$7.6K	—	$29.6K
Q1 26	$236.0K	$260.6K	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$5M	$0	$5M
Q3 23	$3M	$0	$3M
Q4 23	$3M	$0	$3M
Q1 24	$3M	$0	$3M
Q2 24	$3M	$0	$3M
Q3 24	$3M	$0	$3M
Q4 24	$3M	$0	$3M
Q1 25	$3M	$0	$3M
Q2 25	$3M	$0	$3M
Q3 25	$156.1K	$0	$156.1K
Q4 25	$3M	$0	$3M
Q1 26	$3M	$0	$3M
Q2 26	$3M	$0	$3M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 22	0	—	—
Q1 23	125M	—	—
Q2 23	125M	0.0%	—
Q3 23	0	-100.0%	—
Q4 23	0	—	—
Q1 24	125M	—	0.0%
Q2 24	125M	0.0%	0.0%
Q4 24	0	-100.0%	—
Q1 25	22M	—	—
Q2 25	22M	0.0%	-82.7%
Q4 25	1M	-95.0%	-99.1%
Q1 26	22M	+1900.0%	—

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q4 25	$0	2K
Q1 26	$0	2K

Revenue / Employee